Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2022 Oct 25;72(1):87–89. doi: 10.1007/s00262-022-03304-3

Correction to: Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer

Ding Jianyi 1,#, Gan Haili 1,#, Yin Bo 1,#, Yang Meiqin 1, Huang Baoyou 1, Hu Haoran 1, Li Fang 2,, Zheng Qingliang 3,, Han Lingfei 1,
PMCID: PMC9813106  PMID: 36282280

Correction to: Cancer Immunology, Immunotherapy https://doi.org/10.1007/s00262-022-03226-0

The original version of this article unfortunately contained a mistake. The statistical chart in Fig. 1c, d as the same as that in Fig. 1a, b.

Fig. 1.

Fig. 1

Accumulation of MDSCs in cervical cancer patients. a Flow cytometry analysis of PMN-MDSCs in peripheral blood from patients with benign or malignant tumors. Statistical analysis of the frequencies of PMN-MDSCs as a percentage of the mononuclear cells (MCs) population. b Flow cytometry analysis of M-MDSCs in peripheral blood from patients with benign or malignant tumors. Statistical analysis of the frequencies of M-MDSCs as a percentage of the MCs population. c Flow cytometry analysis of the frequency of PMN-MDSCs in the peripheral blood of patients with cervical cancer before and 5 days after surgery. Statistical analysis of the frequencies of PMN-MDSCs as a percentage of the MCs population. d Flow cytometry analysis of the frequency of M-MDSCs in the peripheral blood of patients with cervical cancer before and 5 days after surgery. Statistical analysis of the frequencies of M-MDSCs as a percentage of the MCs population. eg ELISA analysis of the concentrations of IDO, INOS and Arg-1 in the peripheral blood of patients with either malignant or benign cervical tumors. Each point corresponds to an individual patient. Lines indicate the 25th to 75th percentiles. Horizontal lines represent the median value. Data were analyzed using Student’s t test and are expressed as the mean ± SD. Symbols represent statistical significance (*p < 0.05)

The corrected Fig. 1 is given in the following page.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Li Fang, Email: lifang@126.Com.

Zheng Qingliang, Email: Zhengql82@126.com.

Han Lingfei, Email: lingfeihan@126.com.


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES